Videos

APA meeting sessions spotlight how psychiatrists protect wellbeing, embrace creativity, and confront structural racism.

Expert shares the use of liquid formulation ADHD medication and how to discuss with patients.

Learn how common late-life mental illness is, and what new treatments mean for geriatric care.

New data from 245K therapists reveals private practice pressures—insurance, isolation, admin—plus tech tools that could keep clinicians thriving.

Learn how to navigate APA 2026 with intention—spark collaborations, find mentors, and turn overwhelming sessions into lasting professional connections.

Lisdexamfetamine liquid targets ADHD and binge eating, easing pill-swallowing and sensory barriers to improve adherence.

Rajesh Tampi, MD, previews APA talks on geriatric psychiatry.

New report reveals private practice delivers 113.6M mental health sessions, yet business training gaps and access mismatches persist.

Experts discuss rapid cycling and bipolar II, and weigh lithium as an often overlooked treatment option.

Joseph F. Goldberg, MD, urges evidence-based psychiatric deprescribing: continual med reviews, shared decisions, and smarter polypharmacy reduction.

How FDA priority review vouchers speed psychedelic therapy approvals.

Oral zervimesine blocks toxic amyloid and alpha-synuclein oligomers, as Cognition maps FDA strategy for Lewy body trials.

CT-1812 shows promise in Lewy body dementia, stabilizing hallucinations and delusions while easing caregiver distress.

Learn how genetics shape psych med response and dosing.

HHS targets “psychiatric overprescribing,” but experts urge thoughtful deprescribing—stopping ineffective medications while replacing them with evidence-based alternatives tailored to patients.

Tracy Hicks, DNP, FNP/PMHNP-BC, outlines how personalized, team-based care and shared decision-making can improve schizophrenia outcomes in real-world practice.

Learn how to better assess and manage behavioral and psychological symptoms of Alzheimer disease dementia.

The SPAN survey underscores gaps in schizophrenia care access as new treatments emerge, citing coverage and continuity challenges.

Auvelity is now approved for the treatment of Alzheimer disease agitation. Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, weighs in.

FDA approves Axsome’s AXS-05 for Alzheimer’s agitation, backed by multiple trials.

A multicenter study tests SAINT TMS for postpartum depression.

Interim analysis suggests tazbentetol may regrow synapses, improving cognition and schizophrenia symptoms.

Learn how clinicians safely add esketamine nasal spray: REMS setup, two-hour monitoring, vitals checks, referrals, and patient-centered collaboration.

Learn how clinics start esketamine safely: REMS setup, two-hour monitoring, vitals, risk screening, and referral-friendly team care.

AFSP and JED plan a 2026 merger, uniting $75M resources to expand suicide prevention research, school programs, and support for all ages.

DT120, a pharmaceutical-grade formulation of LSD, shows rapid, lasting anxiety relief—single dose, no therapy—with 48% remission at 12 weeks.

Sleep disorders commonly occur in young patients with ADHD. See how to monitor and treat these issues.

Definium’s CMO says FDA talks stay aligned with their plans for advancing DT120 ODT for the treatment of depression, anxiety, and now PTSD.

Learn why patients skip psych meds and how to boost adherence with stigma-free dialogue, routine hacks, family support, and deprescribing tips.

Experts explain why most narcolepsy patients need combination therapy, not one pill, and how new agents cut daytime sleepiness toward normal.